Texas-Developed COVID-19 Vaccine Technology Receives 2nd Authorization

Indonesia-based PT Bio Farma confirmed today it is ready to produce 20 million doses of the IndoVac COVID-19 vaccine in 2022 and 100 million doses by 2024. This innovative vaccine has already received emergency use authorization in Indonesia as an adult primary vaccine.

IndoVac is a recombinant protein-based vaccine technology created and engineered in Houston, Texas, by the Texas Children’s Hospital Center for Vaccine Development (CVD) and Baylor College of Medicine.

PT Bio Farma, is the largest pharmaceutical holding company in Indonesia. licensed IndoVac from BCM Ventures.

Indonesia is seeking Halal Certification for the vaccine. IndoVac successfully completed an audit from the Indonesian Ulema Council Food and Drug Analysis Agency, and the Halal Certification Agency of the Religious Affairs Ministry is expected to grant their approval.

“We hope this positive collaboration can continue to create more innovations in the future. We also expect that IndoVac can also be distributed overseas, apart from being used in Indonesia, so we can help other countries in need and contribute to global vaccine equality,” commented Honesti Basyir, the President Director of Bio Farma, in a press release issued on September 30, 2022.

 PT Bio Farmais currently manufacturing IndoVac primary series vaccines, while a booster vaccine is in the clinical trial stage.

“The need for a safe, effective, low-cost vaccine for middle- to low-income countries is central to the world’s fight against the COVID-19 pandemic,” added Dr. Maria Elena Bottazzi, co-director of the Texas Children’s Hospital CVD and associate dean of the National School of Tropical Medicine at Baylor.

“Without widespread inoculation of populations in the developing world, which must include safe, effective booster doses, additional variants will develop, hindering the progress achieved by currently available vaccines in the USA and other Western countries.”

In 2022, Biological E. Limited licensed a similar vaccine technology from BCM Ventures to create the CorbeVax vaccine, which is available in India and Botswana.

Note: This announcement was manually translated and curated for mobile readership.